Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end
NEW YORK, December 30, 2025, 05:26 ET — Premarket Belite Bio’s U.S.-listed shares were back in focus early Tuesday after the stock surged 6.7% in the prior session, swinging between $151.50 and $169.75 before ending at $165.29. Volume was 309,235 shares, above recent daily levels for the thinly traded biotech. StockAnalysis The move matters because Belite is trying to turn a rare-disease eye drug into a first-in-class launch, and the stock is now trading well above the $154 level at which it last sold new shares in a major December offering. In markets where liquidity thins out near year-end, sharp